All In Biotech

Drug Trial Radar · NCT07116928

Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,244 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,244

Planned (sponsor's estimate)

Start

Nov 30, 2025

Primary completion

Oct 30, 2031

Study completion Dec 30, 2031

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks

Conditions

  • T2DM (Type 2 Diabetes Mellitus)
  • CKD - Chronic Kidney Disease

Interventions

  • ganagliflozinDrug

    50 mg Once daily, 120 weeks

  • PlaceboDrug

    50 mg Once daily, 120 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The average change in eGFR as measured by the total slope of eGFR from baseline to week 120Time frame: Baseline to Week 120

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.